Tim Eley is currently a Director in Clinical Pharmacology and Pharmacometrics at Bristol-Myers Squibb. He received a BS in Pharmacy and a PhD in Pharmaceutical and Biomedical Sciences from the University of Georgia.
He was Assistant Professor at the College of Pharmacy at Nova Southeastern University for 5 years before joining Bristol-Myers Squibb in 2004. Tim supported the atazanavir and efavirenz projects in his first few years at BMS and was closely involved in the pediatric and pregnancy indications for atazanavir before transitioning to the HCV portfolio in 2007. During his time at BMS, Tim has been involved in all phases of clinical drug development, with a focus on the analysis and interpretation of Clinical Pharmacology data.
His resume includes a number of presentations assessing drug interactions and pharmacokinetics of antivirals among special populations in the treatment of HIV and HCV. Additionally, he has been the clinical pharmacologist supporting some groundbreaking studies in the treatment of HCV in the transition to all-oral treatment regimens.
Tim has presented at numerous scientific meetings including AASLD, EASL, ICAAC, IDSA, and both the HIV and HCV Clinical Pharmacology Workshops. He is a member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) and the American Association for Pharmaceutical Scientists (AAPS).